BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 25809628)

  • 21. Pretreatment plasma folate modulates the pharmacodynamic effect of high-dose methotrexate in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma: "folate overrescue" concept revisited.
    Sterba J; Dusek L; Demlova R; Valik D
    Clin Chem; 2006 Apr; 52(4):692-700. PubMed ID: 16455868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
    J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is hypoalbuminemia a risk factor for high-dose methotrexate toxicity in children with acute lymphoblastic leukemia?
    Barakat S; Assem H; Salama M; Mikhael N; El Chazli Y
    J Egypt Natl Canc Inst; 2022 Apr; 34(1):17. PubMed ID: 35434757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Accretion of bone mass in patients treated for childhood acute lymphoblastic leukemia].
    Muszyńska-Rosłan K; Konstantynowicz J; Krawczuk-Rybak M
    Pol Merkur Lekarski; 2007 Oct; 23(136):271-5. PubMed ID: 18293849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
    Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatic dysfunction in children with acute lymphoblastic leukemia in remission: relation to hepatitis infection.
    Meir H; Balawi I; Nayel H; El Karaksy H; El Haddad A
    Med Pediatr Oncol; 2001 Apr; 36(4):469-73. PubMed ID: 11260570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia.
    Pakakasama S; Kanchanakamhaeng K; Kajanachumpol S; Udomsubpayakul U; Sirachainan N; Thithapandha A; Hongeng S
    Ann Hematol; 2007 Aug; 86(8):609-11. PubMed ID: 17323057
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
    Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
    Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effects of different first dose calcium tetrahydro-folate on toxicity and side effects of large dose methotrexate treated standard risk group children with acute lymphoblastic leukemia].
    Fang CQ; Xu WQ; Tang YM; Song H; Shi S; Yang S
    Zhonghua Er Ke Za Zhi; 2004 May; 42(5):392-3. PubMed ID: 15189706
    [No Abstract]   [Full Text] [Related]  

  • 30. Central nervous system prophylaxis with high-dose methotrexate does not give rise to significant electroencephalographic changes in children with acute lymphoblastic leukemia.
    Korinthenberg R; Schneider A; Niemeyer C
    J Child Neurol; 2002 Jun; 17(6):409-12. PubMed ID: 12174959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia.
    Winick N; Shuster JJ; Bowman WP; Borowitz M; Farrow A; Jacaruso D; Buchanan GR; Kamen BA
    J Clin Oncol; 1996 Oct; 14(10):2803-11. PubMed ID: 8874342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CNS late-effects after ALL therapy in childhood. Part III: neuropsychological performance in long-term survivors of childhood ALL: impairments of concentration, attention, and memory.
    Langer T; Martus P; Ottensmeier H; Hertzberg H; Beck JD; Meier W
    Med Pediatr Oncol; 2002 May; 38(5):320-8. PubMed ID: 11979456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solitary serum methotrexate level 36 hours post high-dose methotrexate: A safe, efficacious, and cost-effective strategy to monitor methotrexate toxicities in childhood leukemia in resource-limited centers.
    Khera S; Kapoor R; Pramanik SK
    Pediatr Blood Cancer; 2020 Jul; 67(7):e28387. PubMed ID: 32400952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose methotrexate administration and acute liver damage in children treated for acute lymphoblastic leukemia. A prospective study.
    Locasciulli A; Mura R; Fraschini D; Gornati G; Scovena E; Gervasoni A; Uderzo C; Masera G
    Haematologica; 1992; 77(1):49-53. PubMed ID: 1398282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methotrexate pharmacokinetics in childhood acute lymphoblastic leukaemia: a prognostic value?
    Martelli N; Mathieu O; Margueritte G; Bozonnat MC; Daurès JP; Bressolle F; Hillaire-Buys D; Peyrière H
    J Clin Pharm Ther; 2011 Apr; 36(2):237-45. PubMed ID: 21366654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative study of the long term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation.
    Hill JM; Kornblith AB; Jones D; Freeman A; Holland JF; Glicksman AS; Boyett JM; Lenherr B; Brecher ML; Dubowy R; Kung F; Maurer H; Holland JC
    Cancer; 1998 Jan; 82(1):208-18. PubMed ID: 9428499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Adverse effects of methotrexate in the treatment of acute lymphoblastic leukemia in Uyghur and Han children].
    Hu WW; Nuriding H; Yan M
    Zhongguo Dang Dai Er Ke Za Zhi; 2012 Nov; 14(11):852-5. PubMed ID: 23146734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Correlation study of blood drug concentration and nephrotoxicity on high dose methotrexate therapy in suggestion of diagnosis and treatment of childhood acute lymphoblastic leukemia in the 4th revised edition].
    Cheng DH; Lu H; Zou XQ
    Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):771-774. PubMed ID: 29050116
    [No Abstract]   [Full Text] [Related]  

  • 39. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
    Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
    Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies.
    Xu WQ; Zhang LY; Chen XY; Pan BH; Mao JQ; Song H; Li JY; Tang YM
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):79-86. PubMed ID: 24158402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.